Skip to content

Effect of adjunctive theta Transcranial Alternating current stimulation in opioid dependence

Efficacy of adjunctive theta Transcranial Alternating Current Stimulation on craving, withdrawal, resting and cue related functional connectivity in opioid dependence: A fMRI based single blind randomized sham controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/051152
Enrollment
30
Registered
2023-03-29
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F112- Opioid dependence

Interventions

Intervention1: THETA FREQUENCY HD tACS -ACTIVE: Theta frequency HD- tACS will be administered using a standard equipment (Starstim-32, Neuroelectrics BE, Spa.) using stringent safety measures. The sit

Sponsors

Central Institute of Psychiatry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. In-patient male sex, right handed individuals aged between 18-50 years. 2. Those who fulfill the criteria for Mental and Behavioral disorders due to use of Opioids, Dependence syndrome (F11.2X) according to International Classification of Diseases 10th version (ICD-10)- Diagnostic Criteria for Research (DCR) by World Health Organization in 1993. 3. Drug free or drug naïve patients. 4. Patients without any co morbid substance dependence (except Nicotine and Caffeine). 5. Patients without any co morbid psychiatric disorders. 6. Subjects giving written informed consent. 7. Patients being detoxified with symptomatic management.

Exclusion criteria

Exclusion criteria: 1. Female sex 2. Aged below 18 years and above 50 years. 3. Patients with currently serious medical problem, complicated withdrawal (seizure, delirium) and organic brain disorder. 4. History of any other psychiatric illness or mental retardation. 5. Subjects not willing to give written informed consent. 6. Patients having any metallic implants/parts in body. 7. Patients detoxified with an anti-craving or opioid agonist during period of study.

Design outcomes

Primary

MeasureTime frame
1.Primary outcome is change in craving in patients with opioid dependence assessed by DDQ. 2.Primary outcome is change in craving in patients with opioid dependence assessed by OCDUS. 3.Primary outcome is change in withdrawal in patients with opioid dependence assessed by COWS. Timepoint: 1.change in DDQ measured on Days 2,8,23 2. change in craving assessed by OCDUS measured on Days 2,8,23 3.change in withdrawal assessed by COWS measured on Days 1,2,3,4,5,6,7 and 8

Secondary

MeasureTime frame
1. Secondary outcome is change in resting state functional connectivity of large scale brain networks like the ECN and SN among patients with opioid dependence. 2. Secondary outcome is change in cue related functional connectivity of large scale brain networks like the ECN and SN among patients with opioid dependence. 3. Secondary outcome is change is CGI-I scores from baseline to end in patients with opioid dependence assessed by CGI-I Scale. 4. Number of days to reach COWS score below 5. Timepoint: 1.change in resting state functional connectivity of large scale brain networks like the ECN and SN measured on day 2,8 2. change in cue related functional connectivity of large scale brain networks like the ECN and SN measured on day 2,8 3.change in CGI-I scores from baseline to end assessed by CGI-I Scale on days 1,8,23. 4.Number of days to reach COWS score below 5.

Countries

India

Contacts

Public ContactSourav Khanra

Central Institute of Psychiatry

souravpsy@gmail.com7903302259

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026